Norges Bank
MACK

Norges Bank’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Norges Bank’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-169,464
Closed -$1.65M – 2181
2017
Q2 		$1.65M Sell
169,464
-5,196
-3% -$106K ﹤0.01% 2004
2017
Q1 		$4.23M Buy
174,660
+56,463
+48% +$1.41M ﹤0.01% 1911
2016
Q4 		$3.79M Buy
118,197
+30,039
+34% +$1.28M ﹤0.01% 1905
2016
Q3 		$4.21M Buy
88,158
+21,135
+32% +$877K ﹤0.01% 1901
2016
Q2 		$2.84M Hold
67,023
– – ﹤0.01% 1962
2016
Q1 		$4.41M Sell
67,023
-14,814
-18% -$773K ﹤0.01% 1878
2015
Q4 		$5.09M Buy
81,837
+27,806
+51% +$1.96M ﹤0.01% 1859
2015
Q3 		$3.62M Buy
+54,031
New +$4.41M ﹤0.01% 1933

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank's MACK Position: Q3 2017 in Review

Norges Bank sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 169,464 shares — an estimated $1.65M sold.

Norges Bank first reported a position in MACK in Q3 2015 and held it in 8 quarters. The position peaked at $5.09M in Q4 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Norges Bank reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Norges Bank sold 169,464 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.65M.
  • Norges Bank first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2015 and held it in 8 quarters.
  • Norges Bank's Merrimack Pharmaceuticals, Inc. position peaked at $5.09M in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Norges Bank's 13F filing for Q3 2017, filed 7 Nov 2017.